Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation

Camm, 2012, Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association, Eur. Heart J., 2012, 2719 Krijthe, 2013, Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060, Eur. Heart J., 34, 2746, 10.1093/eurheartj/eht280 Rahman, 2016, Global epidemiology of atrial fibrillation, Nat. Rev. Cardiol., 13, 501, 10.1038/nrcardio.2016.114 Wolf, 1991, Atrial fibrillation as an independent risk factor for stroke: the Framingham study, Stroke, 22, 983, 10.1161/01.STR.22.8.983 Gadsboll, 2017, Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark, Eur. Heart J., 38, 899 Olesen, 2015, Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013, Europace, 17, 187, 10.1093/europace/euu225 Huisman, 2017, The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2, J. Am. Coll. Cardiol., 69, 777, 10.1016/j.jacc.2016.11.061 Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0 Miller, 2012, Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation, Am. J. Cardiol., 110, 453, 10.1016/j.amjcard.2012.03.049 Capodanno, 2013, Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients, Int. J. Cardiol., 167, 1237, 10.1016/j.ijcard.2012.03.148 Dogliotti, 2013, Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin, Clin. Cardiol., 36, 61, 10.1002/clc.22081 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N. Engl. J. Med., 361, 1139, 10.1056/NEJMoa0905561 Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N. Engl. J. Med., 369, 2093, 10.1056/NEJMoa1310907 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N. Engl. J. Med., 365, 981, 10.1056/NEJMoa1107039 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N. Engl. J. Med., 365, 883, 10.1056/NEJMoa1009638 Kirchhof, 2016, 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur. Heart J., 37, 2893, 10.1093/eurheartj/ehw210 López-López, 2017, Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis, BMJ, 359 Mantha, 2012, An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation, Thromb. Haemost., 108, 476, 10.1160/TH12-02-0093 Schneeweiss, 2012, Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation, Circ Cardiovasc Qual Outcomes., 5, 480, 10.1161/CIRCOUTCOMES.112.965988 Lip, 2012, Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation, J. Am. Coll. Cardiol., 60, 738, 10.1016/j.jacc.2012.03.019 Graham, 2016, Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation, JAMA Intern. Med., 176, 1662, 10.1001/jamainternmed.2016.5954 January, 2014, AHA/ACC/HRS guideline for the management of patients with atrial fibrillation, Circulation, 2014, e199, 10.1161/CIR.0000000000000041 Fonarow, 2016, Randomization-there is no substitute, JAMA Cardiol., 1, 633, 10.1001/jamacardio.2016.1792 Danish Medicines Agency, 2013, Danish Medicines Agency website. Nyt om Pradaxa (dabigatran etexilat) og Xarelto (rivaroxaban) Schneeweiss, 2011, Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development, Clin. Pharmacol. Ther., 90, 777, 10.1038/clpt.2011.235 Ray, 2003, Evaluating medication effects outside of clinical trials: new-user designs, Am. J. Epidemiol., 158, 915, 10.1093/aje/kwg231 Lynge, 2011, The Danish National Patient Register, Scand J Public Health., 39, 30, 10.1177/1403494811401482 Kildemoes, 2011, The Danish National Prescription Registry, Scand J Public Health., 39, 38, 10.1177/1403494810394717 Pedersen, 2011, The Danish civil registration system, Scand J Public Health., 39, 22, 10.1177/1403494810387965 Brookhart, 2013, Propensity score methods for confounding control in nonexperimental research, Circ Cardiovasc Qual Outcomes., 6, 604, 10.1161/CIRCOUTCOMES.113.000359 Lamberts, 2017, Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients, J. Am. Heart Assoc., 6, 10.1161/JAHA.116.004517 Larsen, 2016, Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study, BMJ, 353 Nielsen, 2017, Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study, BMJ, 356, j510, 10.1136/bmj.j510 Yao, 2016, Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation, J. Am. Heart Assoc., 5, 10.1161/JAHA.116.003725 Lip, 2017, Effectiveness and safety of standard-dose nonvitamin k antagonist oral anticoagulants and warfarin among patients with atrial fibrillation with a single stroke risk factor: a nationwide cohort study, JAMA Cardiology., 2, 872, 10.1001/jamacardio.2017.1883 Potpara, 2017, Postapproval observational studies of non-vitamin K antagonist oral anticoagulants in atrial fibrillation, JAMA, 317, 1115, 10.1001/jama.2017.1152 Noseworthy, 2016, Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation, Chest, 150, 1302, 10.1016/j.chest.2016.07.013 Abraham, 2017, Gastrointestinal safety of direct oral anticoagulants: a large population-based study, Gastroenterology, 152, 1014, 10.1053/j.gastro.2016.12.018 Staerk, 2018, Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study, J. Intern. Med., 283, 45, 10.1111/joim.12683 Frost, 2007, Trend in mortality after stroke with atrial fibrillation, Am. J. Med., 120, 47, 10.1016/j.amjmed.2005.12.027 Frost, 2004, Alcohol and risk of atrial fibrillation or flutter: a cohort study, Arch. Intern. Med., 164, 1993, 10.1001/archinte.164.18.1993 Rix, 2012, Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry, Scand. Cardiovasc. J., 46, 149, 10.3109/14017431.2012.673728